In recent years, immunotherapy with immune checkpoint inhibitors (ICIs) has been suggested for PitNETs, as the tumors have tumor-infiltrating T lymphocytes and express programmed death ligand 1 (PD-L1) [114–116]. The gene discussed is CD274; the disease is neoplasm.